

# List of Publications

for

## Kim Brøsen

1. **Brøsen K.** Individuelle variationer i lægemidlers oksidative metabolisme. Ugeskr Læger 1984;13:955-9.
- 2\* **Brøsen K,** Gram LF, Schou J, Larsen NE, Thayssen P. Dextropropoxyphene kinetics after single and repeated oral doses in man. Eur J Clin Pharmacol 1985;29:79-84.
- 3\* **Brøsen K,** Otton SV, Gram LF. Sparteine oxidation polymorphism in Denmark. Acta Pharmacol Toxicol 1985;57:357-60.
- \* **Brøsen K,** Gram LF, Klysner R, Bech P. Steady-state levels of imipramine and its metabolites: Significance of dose-dependent kinetics. Eur J Clin Pharmacol 1986;30:43-9.
- 5\* **Brøsen K,** Otton SV, Gram LF. Sparteine oxidation polymorphism - A family study. Br J Clin Pharmacol 1986;21:661-7.
- 6\* Brinn R, Brøsen K, Gram LF, Haghfelt T, Otton SV. Sparteine oxidation is practically abolished in quinidine-treated patients. Br J Clin Pharmacol 1986;22:194-7.
- 7\* **Brøsen K,** Klysner R, Gram LF, Otton SV, Bech P, Bertilsson L. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. Eur J Clin Pharmacol 1986;30:679-84.
- 8\* **Brøsen K.** Sparteine oxidation polymorphism in Greenlanders living in Denmark. Br J Clin Pharmacol 1986;22:415-9.
- 9\* **Brøsen K,** Otton SV, Gram LF. Imipramine demethylation and hydroxylation: Impact of the sparteine oxidation phenotype. Clin Pharmacol Ther 1986;40:543-9.
- 10\* Gram LF, **Brøsen K,** Christensen P, Kragh-Sørensen P. Pharmacokinetic considerations relevant to the pharmacodynamics of antidepressants. In: Dahl SG, Gram LF, Paul SM, Potter WZ (eds): Clinical Pharmacology in Psychiatry. Springer Verlag 1987, pp. 184-92.
- 11\* **Brøsen K,** Gram LF, Haghfelt T, Bertilsson L. Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. Pharmacol Toxicol 1987;60:312-4.
12. Gram LF, **Brøsen K.** Polymorphisme génétique de l'oxydation des médicaments psychotropes. Acta Med Inter Psychiatrie 1987;4:1368-74.
13. **Brøsen K.** Farmakokinetik og grundlaget for lægemiddeldosering og terapikontrol. Månedsskr Prakt Lægeger 1987;65:889-96.

- 14\* Davidsen F, Haghfelt T, Gram LF, **Brøsen K**. Adverse drug reactions and drug non-compliance as primary cause of admission to a cardiology department. *Eur J Clin Pharmacol* 1988;34:83-6.
- 15\* **Brøsen K**, Gram LF. First-pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype. *Clin Pharmacol Ther* 1988;43:400-6.
16. **Brøsen K**. Farmakogenetik. *Månedsskr Prakt Lægeger* 1988;66:487-93.
17. **Brøsen K**. The relationship between imipramine metabolism and the sparteine oxidation polymorphism. (Thesis). *Dan Med Bull* 1988;35:460-8.
- 18\* Drøhse A, Bathum L, **Brøsen K**, Gram LF. Mephenytoin and sparteine oxidation: Genetic polymorphisms in Denmark. *Br J Clin Pharmacol* 1989;27:620-5.
- 19\* Rotwitt LB, Rosholm J-U, **Brøsen K**, Gram LF. Art og omfang af lægemiddelinformation til alment praktiserende læger. *Ugeskr Læger* 1989;151:647-50.
- 20\* **Brøsen K**, Gram LF. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. *Eur J Clin Pharmacol* 1989;36:537-47.
- 21\* **Brøsen K**, Gram LF. Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine. *Eur J Clin Pharmacol* 1989;37:155-60.
- 22\* Sindrup SH, Ejlersen B, Frøland A, Sindrup EH, **Brøsen K**, Gram LF. Imipramine treatment in diabetic neuropathy: Relief of subjective symptoms without changes in measures of peripheral and autonomic nerve function. *Eur J Clin Pharmacol* 1989;37:151-3.
- 23\* Gram LF, **Brøsen K**, Kragh-Sørensen P, Christensen P. Steady-state levels of E- and Z-10-OH-nortriptyline in nortriptyline treated patients: Significance of concurrent medication and the sparteine oxidation phenotype. *Ther Drug Monit* 1989;11:508-14.
24. Gram LF, **Brøsen K**. Genetic polymorphism in drug oxidation: Implications for the clinical use of tricyclic antidepressants. *In*: Lerer B, Gershon S (eds): *New directions in affective disorders*. Springer Verlag 1989, p. 623-7.
25. **Brøsen K**, Gram LF. Pharmacokinetic and clinical significance of genetic variability in psychotropic drug metabolism. *In*: Dahl SG, Gram LF (eds): *Clinical Pharmacology in Psychiatry: Molecular Studies to Clinical Reality*. Springer Verlag 1989, p. 192-200.
26. Gram LF, **Brøsen K**. Inhibitors of the microsomal oxidation of psychotropic drugs: Selectivity and clinical significance. *In*: Dahl SG, Gram LF (eds): *Clinical Pharmacology in Psychiatry: Molecular Studies to Clinical Reality*. Springer Verlag 1989, p. 172-80.
27. Gram LF, **Brøsen K**. Conditions under which genetic polymorphisms are clinically relevant. *In*: Alván G et al. (eds): "Consensus Conference on Pharmacogenetics", Besançon 24-25 October 1989. Office for Official Publications of the European Communities, Luxemburg 1990, p. 87-96.
- 28\* **Brøsen K**, Davidsen F, Gram LF. Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man. *Br J Clin Pharmacol* 1990;29:248-53.

- 29\* **Brøsen K.** Recent developments in hepatic drug oxidation - implications for clinical pharmacokinetics. *Clin Pharmacokinet* 1990;18:220-39.
- 30\* Nielsen MD, **Brøsen K**, Gram LF. A dose-effect study on the in vivo inhibitory effect of quinidine on the sparteine oxidation in man. *Br J Clin Pharmacol* 1990;29:299-304.
- 31\* Danish University Antidepressant Group (DUAG). Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. *J Affective Disord* 1990;18:289-99.
- 32\* Hallas J, Harvald B, Gram LF, Grodum E, **Brøsen K**, Haghfelt T, Damsbo N. Drug related hospital admissions. The role of definitions and intensity of data collection, and the possibility of prevention. *J Int Med* 1990;228:83-90.
- 33\* Sindrup SH, Gram LF, **Brøsen K**, Eshøj O, Mogensen EF. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. *Pain* 1990;42:135-44.
- 34\* Zeugin TB, **Brøsen K**, Meyer UA. Determination of imipramine and seven of its metabolites in human liver microsomes by a high performance liquid chromatographic method. *Anal Biochem* 1990;189:99-102.
- 35\* Sindrup SH, **Brøsen K**, Gram LF. Non-linear kinetics of imipramine in low and medium plasma level ranges. *Ther D Monit* 1990;12:445-9.
- 36\* Sindrup SH, Gram LF, Skjold T, Grodum E, **Brøsen K**, Beck-Nielsen H. Clomipramine versus desipramine versus placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study. *Br J Clin Pharmacol* 1990;30:683-91.
- 37\* Sindrup SH, **Brøsen K**, Bjerring P, Arendt-Nielsen L, Larsen U, Angelo HR, Gram LF. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not in poor metabolizers of sparteine. *Clin Pharmacol Ther* 1990;48:686-93.
- 38\* Skjelbo E, **Brøsen K**, Hallas J, Gram LF. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. *Clin Pharmacol Ther* 1991;49:18-23.
39. **Brøsen K.** Cytokrom P450 gen-superfamiliens betydning for lægemidlers kliniske farmakokinetik. *Ugeskr Læger* 1991;153:417-22.
40. Petersen P, **Brøsen K.** Svær nortriptylin-forgiftning hos langsom omdanner af sparteintypen. *Ugeskr Læger* 1991;153:443-4.
- 41\* Jensen J, Nielsen LH, Lyhne N, Hallas J, **Brøsen K**, Gram LF. Drugs and femoral neck fracture - a case-control study. *J Int Med* 1991;229:29-33.
- 42\* **Brøsen K**, Zeugin TB, Meyer UA. Role of P450IID6, the target of the sparteine/debrisoquin oxidation polymorphism, in the metabolism of imipramine. *Clin Pharmacol Ther* 1991;49:609-17.

- 43\* Clasen K, Madsen L, **Brøsen K** K, Albøge K, Misfeldt S, Gram LF. Sparteine and mephenytoin oxidation: Genetic polymorphisms in East- and West Greenland. *Clin Pharmacol Ther* 1991;49:624-31.
- 44\* **Brøsen K**, Gram LF, Kragh-Sørensen P. Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine and mephenytoin. *Ther Drug Monit* 1991;13:177-82.
- 45\* Ward SA, Helsby NA, Skjelbo E, **Brøsen K**, Gram LF, Breckenridge AM. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism - a panel study. *Br J Clin Pharmacol* 1991;31:689-92.
46. Rask PH, Krarup G, Kragh-Sørensen P, Andersen E, **Brøsen K** et al. Terapistyring af perfenazinbehandling ved paranoide tilstande - organisatoriske aspekter. *Ugeskr Læger* 1991;153:2336-9.
47. Kjeldsen CS, Larsen NE, Kragh-Sørensen P, Andersen E, **Brøsen K** et al. Terapistyring af perfenazinbehandling ved paranoide tilstande. Kliniske aspekter. *Ugeskr Læger* 1991;153:2339-43.
- 48\* Brøsen K, Skjelbo E. Fluoxetine and norfluoxetine are potent inhibitors of P450IID6 - the source of the sparteine/debrisoquine oxidation polymorphism. *Br J Clin Pharmacol* 1991;32:136-7.
- 49\* Hallas J, Worm J, Beck-Nielsen J, Gram LF, Grodum E, Damsbo N, **Brøsen K**. Drug related events and drug utilization in patients admitted to a geriatric hospital department. *Dan Med Bull* 1991;38:417-20.
50. **Brøsen K**, Secher B (red.). *Lægemiddelinformation 1991*. (Udgivet af Lægemiddeludvalget, Odense Sygehus).
- 51\* Hallas J, Gram LF, Grodum E, Damsbo N, **Brøsen K** et al. Drug related admissions to medical wards: A population based survey. *Br J Clin Pharmacol* 1992;33:61-8.
52. Gram LF, **Brøsen K**, Sindrup SH, Skjelbo E. Clinical relevance of genetic polymorphisms in drug oxidation. In: Brès J, Davis G (eds): *Pharmacocinétique: De la recherche à la clinique*. John Libbey's Eurotext 1992, p. 40-7.
- 53\* Sindrup SH, **Brøsen K**, Gram LF, Hallas J, Skjelbo E, Allen A, Allen GD, Cooper SM, Mellows G, Tasker TCG, Zussman BD. The relationship between paroxetine and the sparteine oxidation polymorphism. *Clin Pharmacol Ther* 1992;51:278-87.
- 54\* Sindrup SH, **Brøsen K**, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine - Nonlinearity and relation to the sparteine oxidation polymorphism. *Clin Pharmacol Ther* 1992;51:288-95.
55. **Brøsen K**. Lægemiddelinteraktioner. I: Kristensen MB, Bundgaard H, Jensen K (eds). *Lægemiddelkataloget 1992*:373-400.
- 56\* Sindrup SH, Arendt-Nielsen L, **Brøsen K**, Bjerring P, Angelo HR, Eriksen B, Gram LF. The effect of quinidine on the analgesic effect of codeine. *Eur J Clin Pharmacol* 1992;42:587-92.

- 57\*. Sindrup SH, Tuxen C, Gram LF, Grodum E, Skjold T, **Brøsen K**, Beck-Nielsen H. Lack of effect of mianserin on the symptoms of diabetic neuropathy. *Eur J Clin Pharmacol* 1992;43:251-5.
- 58\* Skjelbo E, Brøsen K. Inhibitors of imipramine metabolism by human liver microsomes. *Br J Clin Pharmacol* 1992;34:256-61.
- 59\* Nielsen KK, **Brøsen K**, Gram LF, DUAG. Steady-state plasma levels of clomipramine and its metabolites: Impact of the sparteine/debrisoquine oxidation polymorphism. *Eur J Clin Pharmacol* 1992;43:405-11.
- 60\* **Brøsen K**, Sindrup SH, Skjelbo E, Nielsen KK, Gram LF. Clinical relevance of genetic polymorphism in the oxidation of psychotropic drugs. *In*: Laux G and Riederer P (eds). *Plasma Spiegel Bestimmung von Psychopharmaka*. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart 1992, p. 19-20.
- 61 **Brøsen K**. Variability in kinetics and response in humans. *The Toxicology Forum*, 1992, Annual European Meeting, Copenhagen, Denmark, June 1-5. CASET Associates Ltd., 3927 Old Lee Highway, Fairfax, VA 22030, USA, p. 451-63.
- 62.\* Sindrup SH, Bjerre U, Dejgaard A, **Brøsen K**, Aaes-Jørgensen T, Gram LF. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. *Clin Pharmacol Ther* 1992;52:547-52.
- 63\* Sindrup SH, **Brøsen K**, Hansen MGJ, Aaes-Jørgensen T, Overø KF, Gram LF. Pharmacokinetics of citalopram in relation to the sparteine and mephenytoin oxidation polymorphism. *Ther Drug Monit* 1993;15:11-7.
- 64\* Gram LF, Hansen MGJ, Sindrup SH, **Brøsen K**, Poulsen JH, Aaes-Jørgensen T, Overø KF. Citalopram: Interaction studies with levomepromazine, imipramine and lithium. *Ther Drug Monit* 1993;15:18-24.
- 65\* Nielsen KK, **Brøsen K**. High Performance Liquid Chromatography of imipramine and six metabolites in human plasma and urine. *J Chromatogr* 1993;612:87-94.
66. Gram LF, **Brøsen K**, Sindrup SH, Skjelbo E. Risk factors in elderly taking psychotropic drugs: Significance of genetic polymorphism in drug oxidation. *Nord J Psychiatry (suppl.)* 1993;28:85-9.
67. **Brøsen K**, Sindrup SH, Skjelbo E, Nielsen KK, Gram LF. Role of genetic polymorphism in psychopharmacology - an update. *In*: Gram LF, Balant LP, Meltzer HY, Dahl SG (eds). *Proceedings of the "6th International Meeting on Clinical Pharmacology in Psychiatry"*, Geneva, June 5-7 1991, p. 199-211.
- 68\* Skjelbo E, Gram LF, **Brøsen K**. The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). - A population study. *Br J Clin Pharmacol* 1993;35:331-4.
- 69\* Nielsen KK, **Brøsen K**. High Performance Liquid Chromatography of clomipramine and metabolites in human plasma and urine. *Ther Drug Monit* 1993;15:122-8.

70. Stage K, **Brøsen K.** Manglende effekt af nortriptylin hos en hurtig omdanner af spartein. Ugeskr Læger 1993;155:1561-3.
- 7\* **Brøsen K,** Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45:1211-4.
- 72\* **Brøsen K,** Hansen MGJ, Kramer Nielsen K, Sindrup SH, Gram LF. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993;44:349-55.
- 73\* Sindrup SH, Poulsen L, **Brøsen K,** Arendt-Nielsen L, Gram LF. Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers? Pain 1993;53:335-9.
- 74\* Gram LF, **Brøsen K.** Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Br J Clin Pharmacol 1993;35:649-52.
- 75\* **Brøsen K,** Skjelbo E, Flachs H. Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark. Br J Clin Pharmacol 1993;36:105-8.
- 76\* **Brøsen K,** Kragh-Sørensen P. Concomitant intake of nortriptyline and carbamazepine. Ther Drug Monit 1993;15:258-60.
77. **Brøsen K.** Isozyme specific drug oxidation: Genetic polymorphism and drug-drug interactions. Nordic J Psychiat 1993;47(suppl.39):21-6.
- 78\* DUAG. Moclobemide: A reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affective Disord 1993;28:105-16.
- 79\* Ranek L, Dalhoff K, Poulsen HE, **Brøsen K,** Flachs H, Loft S. Wantzin P. Drug metabolism and genetic polymorphism in subjects with previous halothane hepatitis. Scand J Gastroenterol 1993;28(8):677-80.
- 80\* **Brøsen K.** The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin Investig 1993;71:1002-9.
81. **Brøsen K.** CYP2D6-genotypebestemmelse. Ugeskr Læger 1993;155/46:3779-80.
82. **Brøsen K.** (red.). Lægemiddelinformation 1994. (Udgivet af Lægemiddeludvalget, Odense Universitetshospital).
83. **Brøsen K.** Farmakogenetik, Kap. 4 I: Kampmann JP et al. (eds): Basal og Klinisk Farmakologi (FADL 1994).
- 84\* Nielsen KK, **Brøsen K,** Hansen MGJ, Gram LF. Single dose kinetics of clomipramine: Relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin Pharmacol Ther 1994;55:518-27.
- 85\* **Brøsen K,** Nielsen PN, Brusgaard K, Gram LF, Skjødt K. CYP2D6 genotype determination in the Danish population. Eur J Clin Pharmacol 1994;47:221-5.

- 86\* Nielsen F, Nielsen KK, **Brøsen K**. Determination of quinidine, dihydroquinidine, (3S)-3-hydroxyquinidine, and quinidine-N-oxide in plasma and urine by high-performance liquid chromatography. *J Chromatogr* 1994;B660:103-10.
- 87\* Nielsen KK, **Brøsen K**, Hansen MGJ, Gram LF. Glucuronidation clearance of 8-hydroxycyclomipramine in relation to the sparteine and mephenytoin phenotype. *Eur J Clin Pharmacol* 1994;47:209-10.
- 88\* Rasmussen BB, Nielsen KK, **Brøsen K**. Determination of theophylline metabolites in human liver microsomes by high-performance liquid chromatography. *Anal Biochem* 1994;222:9-13.
- 89\* Başçi NE, **Brøsen K**, Bozkurt A, Isimer A, Sayal A, Kayaalp SO. S-mephenytoin, sparteine and debrisoquine oxidation: Genetic polymorphisms in the Turkish population. *Br J Clin Pharmacol* 1994;38:463-5.
90. **Brøsen K**. Øger langtidsbehandling med omeprazol risikoen for cancer? *Ugeskr Læger* 1994;41:6017-8.
- 91\* Poulsen L, Arendt-Nielsen L, **Brøsen K**, Nielsen KK, Gram LF, Sindrup SH. The hypoalgesic effect of imipramine in different human experimental pain models. *Pain* 1995;60:287-93.
- 92\* Rasmussen BB, Mäenpää J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt J, **Brøsen K**. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: Potent inhibition by fluvoxamine. *Br J Clin Pharmacol* 1995;39:151-9.
- 93\* Madsen H, Nielsen KK, **Brøsen K**. Imipramine metabolism in relation to the sparteine and the mephenytoin oxidation polymorphisms. *Br J Clin Pharmacol* 1995;39:433-9.
- 94\* Gram LF, Guentert TW, Grange S, Vistisen K, **Brøsen K**. Moclobemide - A substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2. - A panel study. *Clin Pharmacol Ther* 1995;57:670-7.
- 95\* **Brøsen K**, de Morais SMF, Meyer UA, Goldstein JA. A multifamily study on the relationship between *CYP2C19* genotype and S-mephenytoin oxidation phenotype. *Pharmacogenetics* 1995;5:312-7.
96. Nielsen F, Rosholm J-U, **Brøsen K**. Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism. *Eur J Clin Pharmacol* 1995;48:501-4.
97. **Brøsen K**. Drug interactions and the cytochrome P450 system. The role of cytochrome P4501A2. *Clin Pharmacokinet* 1995;29C(suppl.1):20-5.
98. **Brøsen K**. Specific inhibitors of enzymes of drug metabolism. In: COST B1 conference on variability and specificity in drug metabolism. Eds: Alván G et al. 1995, p. 159-67.
99. Gram LF, **Brøsen K**, Sindrup S, Skjelbo E. Genetic and interethnic variability in drug metabolism: What are the clinical consequences? In: COST B1 conference on variability and specificity in drug metabolism. Eds: Alván G et al. 1995, p. 235-45.

- 100\* Sindrup SH, **Brøsen K**. The pharmacogenetics of codeine hypoalgesia. *Pharmacogenetics* 1995;5:335-46.
- 101\* **Brøsen K**, Rasmussen BB. Selective serotonin re-uptake inhibitors: Pharmacokinetics and drug interactions. In: J.P. Feighner and W.F. Boyer (eds.) *Selective Serotonin Re-uptake Inhibitors: Advances in Basic Research and Clinical Practice*. Second Edition, John Wiley & Sons Ltd. 1996, pp. 87-108.
- 102\* Sindrup SH, Hofmann U, Asmussen J, Mikus G, **Brøsen K**, Nielsen F, Ingwersen SH, Broen Christensen C. Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. *Eur J Clin Pharmacol* 1996;49:503-9.
- 103\* Rasmussen BB, **Brøsen K**. Determination of theophylline and its metabolites in human urine and plasma by high-performance liquid chromatography. *J Chromatogr, Biomed. Applications* 1996;676:169-74.
- 104\* Rasmussen BB, **Brøsen K**. Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and *N*-acetyltransferase activity in humans. *Ther Drug Monit* 1996;18:254-62.
- 105\* Skjelbo E, Mutabingwa TK, Bygbjerg I, Nielsen KK, Gram LF, **Brøsen K**. Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the *S*-mephenytoin oxidation in Tanzanians. *Clin Pharmacol Ther* 1996;59:304-11.
- 106\* Nielsen KK, Flinois JP, Beaune P, **Brøsen K**. The biotransformation of clomipramine *in vitro*, identification of the cytochrome P450s responsible for the separate metabolic pathways. *J Pharmacol Exp Ther* 1996;277:1659-64.
107. **Brøsen K**. Are pharmacokinetic drug interactions with the SSRIs an issue? *Int Clin Psychopharmacol* 1996;11:23-7.
108. Jeppesen U, Loft S, Poulsen HE, **Brøsen K**. A fluvoxamine-caffeine interaction study. *Pharmacogenetics* 1996;6:213-22.
109. **Brøsen K**. Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. *Ther Drug Monit* 1996;18:393-6.
- 110\* Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, **Brøsen K**. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. *Eur J Clin Pharmacol* 1996;51:73-8.
- 111\* Poulsen L, Arendt-Nielsen, L, **Brøsen K**, Sindrup SH. The hypoalgesic effect of tramadol in relation to CYP2D6. *Clin Pharmacol Ther* 1996;60:636-44.
- 112\* Madsen H, Hansen TS, **Brøsen K**. Imipramine metabolism in relation to the sparteine oxidation polymorphism - a family study. *Pharmacogenetics* 1996;6:513-9.
- 113\* Poulsen L, **Brøsen K**, Arendt-Nielsen L, Gram LF, Elbæk K, Sindrup SH. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. *Eur J Clin Pharmacol* 1996;51:289-95.

114. **Brøsen K**, Skjelbo E, Nielsen KK. Imipramine: a model drug for P450 research. In: Johnson EF, Waterman MR (eds.): *Methods in Enzymology*, vol 272, 1996, p. 177-86.
115. Sonne J, Christensen HR, Gram LF, Kampmann JP, **Brøsen K**. Dansk statusartikel om klinisk farmakologi. *Ugeskr Læger* 1996/7.
- 116\* Christensen PM, Gøtzsche PC, **Brøsen K**. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis. *Eur J Clin Pharmacol* 1997;51:389-93.
- 117\* Rasmussen BB, Jeppesen U, Gaist D, **Brøsen K**. Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. *Ther Drug Monit* 1997;19:56-62.
- 118\* Madsen H, Rasmussen BB, **Brøsen K**. Imipramine demethylation in vivo: impact of CYP1A2, CYP2C19 and CYP3A4. *Clin Pharmacol Ther* 1997;61:319-24.
- 119\* Rasmussen BB, **Brøsen K**. Theophylline has no advantages over caffeine as a putative model drug for assessing CYP1A2 activity in humans. *Br J Clin Pharmacol* 1997;43:253-8.
- 120\* Sindrup SH, Poulsen L, **Brøsen K**. Pain modulation and the genetic polymorphic enzyme CYP2D6. *Analgesia* 1996;2:259-65.
- 121\* Poulsen L, Arendt-Nielsen L, **Brøsen K**, Gram LF, Sindrup SH. Different effect of naloxone on pain perception in extensive and poor metabolizers of sparteine? *Analgesia* 1996;2:255-8.
- 122\* Madsen H, Møller Rasmussen J, **Brøsen K**. Interaction between tramadol and phenprocoumon. *The Lancet* 1997;350:637.
123. Madsen H, Møller Rasmussen J, **Brøsen K**. Author's reply. *Lancet* 1997;350:1553.
- 124\* Jeppesen U, Møller Rasmussen J, **Brøsen K**. Clinically important interaction between azathioprine (Imurel®) and phenprocoumar (Marcoumar®). *Eur J Clin Pharmacol* 1997;52:503-4.
- 125\* Jeppesen U, Rasmussen BB, **Brøsen K**. Fluvoxamine inhibits the CYP2C19 catalyzed bioactivation of chloroguanide. *Clin Pharmacol Ther* 1997;62:279-86.
- 126\* Bathum L, Hansen TS, Hørder M, **Brøsen K**. A dual label oligonucleotide ligation assay for detection of the CYP2C19 1, CYP2C19 2 and CYP2C19 3 alleles involving time-resolved fluorometry. *Ther Drug Monit* 1998;20:1-6.
- 127\* Christensen PM, Gøtzsche P, **Brøsen K**. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis. *Pharmacogenetics* 1998;8:473-9.
- 128\* Bathum L, Johansson I, Ingelman-Sundberg M, Hørder M, **Brøsen K**. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction. *Pharmacogenetics* 1998;8:119-23.

129. Skjelbo E, **Brøsen K**. En interaktion imellem paroxetin og clomipramin som mulig årsag til indlæggelse på medicinsk afdeling. *Ugeskr Læger* 1998;160:1257-58.
- 130\* Hansen LL, Larsen JT, **Brøsen K**. Determination of tacrine and its metabolites in human plasma and urine by high-performance liquid chromatography and fluorescence detection. *J Chromatogr B* 1998;712:183-91.
- 131\* Poulsen L, Riishede L, **Brøsen K**, Clemensen S, Sindrup SH. Codeine in post-operative pain. Study of the influence of sparteine phenotype and serum concentrations of morphine and morphine-6-glucuronide. *Eur J Clin Pharmacol* 1998;54:451-4.
- 132\* Andersen M, Arnberg A, **Brøsen K**, Gram LF, Petersen KB. Lægemedelinformationscentralen ved Center for Klinisk Farmakologi i Odense. *Ugeskr Læger* 1998;60:3234.
- 133\* Bathum L, Andersen-Ranberg K, Boldsen J, **Brøsen K**, Jeune B. Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevity. Role of CYP2D6 and CYP2C19 in longevity. *Eur J Clin Pharmacol* 1998;54:427-30.
134. Sindrup SH, **Brøsen K**. Kombinationspræparater af codein og paracetamol. *Ugeskr Læger* 1998;160(4):448-9.
- 135\* Rasmussen BB, Nielsen TL, **Brøsen K**. Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. *Pharmacol Toxicol* 1998;83:240-5.
136. **Brøsen K**. Differences in interactions of SSRIs. *Int J Clin Psychopharmacol* 1998;13(suppl.5):S45-7.
- 137\* Buur Rasmussen B, Nielsen TL, **Brøsen K**. Fluvoxamine inhibits the CYP2C19-catalyzed metabolism of proguanil in vitro. *Eur J Clin Pharmacol* 1998;54:735-40.
- 138\* Kortunay S, Bozkurt A, Bathum L, Başçi NE, Calgüneri M, **Brøsen K**, Kayaalp SO. CYP2D6 polymorphism in systemic lupus erythematosus patients. *Eur J Clin Pharmacol* 1999;55:21-5.
- 139\* Fjordside L, Jeppesen U, Eap CB, Powell K, Baumann P, **Brøsen K**. The stereoselective metabolism of fluoxetine in poor and extensive metabolisers of sparteine. *Pharmacogenetics* 1999;9:55-60.
140. Danish University Antidepressant Group (DUAG). Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics. *Clin Pharmacol Ther* 1999;66(2):152-65.
- 141\* Nielsen TL, Rasmussen BB, Flinois J-P, Beaune P, **Brøsen K**. In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P4503A4 activity in human liver microsomes. *J Pharmacol Exp Ther* 1999;289:31-7.
142. **Brøsen K** (edt.). A Guide to Training in Clinical Pharmacology in Europe. European Association for Clinical Pharmacology and Therapeutics. Odense University Press 1999, pp. 340.

143. **Brøsen K.** Klinisk farmakologi – hvad skal vi med det? Ugeskr Læger 1999;161/26:3981.
- 144\* Teilmann Larsen J, Lindal Hansen L, Spigset O, **Brøsen K.** Fluvoxamine is a potent inhibitor of tacrine metabolism in vivo. Eur J Clin Pharmacol 1999;55:375-82.
- 145\* Damkier P, Hansen LL, **Brøsen K.** Effect of fluvoxamine on the pharmacokinetics of quinidine. Eur J Clin Pharmacol 1999;55:451-56.
- 146\* Ibeanu GC, Blaisdell J, Ferguson RJ, Ghanayem BI, **Brøsen K,** Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Goldstein JA. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther 1999;290:635-40.
- 147\* Kortunay S, Bozkurt A, Bathum L, Basci NE, Calguneri M, **Brøsen K,** Kayaalp SO. CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosus. Ann Rheum Dis 1999;58:182-5.
148. Senderovitz T, Heisterberg J, Christophersen B. Kompendium i farmakologi. FADLs Forlag 1999, pp. 283. Boganmeldelse af **Brøsen K.** I: Ugeskr Læger 1999;161/34:4755.
149. **Brøsen K,** Kampmann JP. Metoder i klinisk farmakologisk forskning (inkl. GCP). I: Sundhedsvidenskabelig Forskning. Andersen D et al. (eds.). FADLs Forlag 1999, p. 427-58.
- 150\* Bathum L, Skjelbo E, Mutabingwa TK, Madsen K, Hørder M, **Brøsen K.** Pheno- and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. Br J Clin Pharmacol 1999;48:395-401.
- 151\* Damkier P, Hansen LL, **Brøsen K.** Rifampicin treatment greatly increases the apparent oral clearance of quinidine. Pharmacol Toxicol 1999;85:257-62.
- 152.\* Larsen JT, Hansen LL, **Brøsen K.** Tacrine is probably not an ideal probe drug for measuring CYP1A2 activity in vivo. Br J Clin Pharmacol 1999;48:663-8.
- 153\* Damkier P, Hansen LL, **Brøsen K.** Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Br J Clin Pharmacol 1999;48:829-38.
154. Kampmann JP, **Brøsen K,** Nielsen-Kudsk F, Nyborg NCB. Basal og Klinisk Farmakologi. 2. udgave, FADL's Forlag 1999, pp. 806.
155. **Brøsen K.** Lægemidlers skæbne i organismen. Kap. 3. I: Kampmann JP, Brøsen K, Nielsen-Kudsk F, Nyborg NCB, red. Basal og Klinisk Farmakologi. 2. udgave, FADL's Forlag 1999, p. 33-58.
156. **Brøsen K.** Lægemidlers elimination. Kap. 4. I: Kampmann JP, Brøsen K, Nielsen-Kudsk F, Nyborg NCB, red.. Basal og Klinisk Farmakologi. 2. udgave, FADL's Forlag 1999, p. 59-71.
157. **Brøsen K.** Farmakogenetik. Kap. 5. I: Kampmann JP, Brøsen K, Nielsen-Kudsk F, Nyborg NCB, red.. Basal og Klinisk Farmakologi. 2. udgave, FADL's Forlag 1999, p. 73-77.

158. **Brøsen K**, Christensen HR. Lægemiddelinteraktioner. Kap. 59. I: Kampmann JP, Brøsen K, Nielsen-Kudsk F, Nyborg NCB, red.. Basal og Klinisk Farmakologi. 2. udgave. FADL's Forlag 1999, p. 667-71.
159. Madsen H, **Brøsen K**. Lægemidler og graviditet. Kap. 63. I: Kampmann JP, Brøsen K, Nielsen-Kudsk F, Nyborg NCB, red.. Basal og Klinisk Farmakologi. 2. udgave. FADL's Forlag 1999, p. 705-14.
160. **Brøsen K**. Styret terapi. Kap. 67. I: Kampmann JP, Brøsen K, Nielsen-Kudsk F, Nyborg NCB, red.. Basal og Klinisk Farmakologi. 2. udgave. FADL's Forlag 1999, p. 743-46.
161. **Brøsen K**, Kampmann JP. Klinisk afprøvning af lægemidler. Kap. 68. I: Kampmann JP, Brøsen K, Nielsen-Kudsk F, Nyborg NCB, red.. Basal og Klinisk Farmakologi. 2. udgave. FADL's Forlag 1999, p. 747-55.
- 162\* Buur Rasmussen B, **Brøsen K**. Cytochrome P450 and therapeutic drug monitoring with respect to clozapine. *Eur Neuropsychopharmacol* 1999;9:453-9.
- 163\* Hansen LL, **Brøsen K**. Quantitative determination of tolbutamide and its metabolites in human plasma and urine by high-performance liquid chromatography and UV detection. *Ther Drug Monit* 1999;21:669-71.
- 164\* Sindrup SH, Madsen C, **Brøsen K**, Jensen TS. The effect of tramadol in painful polyneuropathy in relation to serum drug and metabolite levels. *Clin Pharmacol Ther* 1999;66:636-41.
- 165\* Sindrup SH, Andersen G, Madsen C, Smith T, **Brøsen K**, Jensen TS. Tramadol relieves pain and allodynia in polyneuropathy. A randomized, double-blind, controlled trial. *Pain* 1999;83:85-90.
- 166\* Rasmussen BB, **Brøsen K**. Is therapeutic drug monitoring a case for optimising clinical outcome and avoiding interactions of the selective serotonin re-uptake inhibitors? *Ther Drug Monit* 2000;22:143-54.
167. **Brøsen K**. Etniske variationer med hensyn til genetisk polymorfi i metabolismen af lægemidler. *Ugeskr Læger* 2000;162:818.
168. **Brøsen K**. Antiarrhythmics. Chapter 45. In: *Metabolic Drug Interactions* (Levy RH et al., eds.). Lippincott, Williams & Wilkins 2000, Philadelphia, USA, p. 603-14.
- 169\* Damkier P, **Brøsen K**. Quinidine as a probe for CYP3A4 activity: Intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19 and CYP2D6. *Clin Pharmacol Ther* 2000;68:199-209.
- 170\* Justesen US, **Brøsen K**, Pedersen C. Hiv-proteasehæmmere og interaktioner. *Ugeskr Læger* 2000;162:4677-81.
- 171\* Kirchheiner J, **Brøsen K**, Dahl ML, Gram LF, Kasper S, Roots I, Sjöqvist F, Spina E, Brockmüller J. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. *Acta Psychiatr Scand* 2001;104:173-92.

172. Larsen J, Arnberg A, **Brøsen K**. Tramadol og oxazepam. *Ugeskr Læger* 2001;163:458-60.
- 173\* Madsen H, Enggaard TP, Hansen LL, Klitgaard NA, **Brøsen K**. Fluvoxamine inhibits the CYP2C19 catalyzed biotransformation of tolbutamide. *Clin Pharmacol Ther* 2001;69:41-7.
- 174\* Bergmann TK, Bathum L, **Brøsen K**. Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6. *Eur J Clin Pharmacol* 2001;57:123-7.
- 175\* **Brøsen K**, Naranjo CA. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. *Eur Neuropsychopharmacol* 2001; 11:275-283.
176. **Brøsen K**, Nedergaard OA, Orme. Abstract Book 5<sup>th</sup> EACPT Congress. *Pharmacol Toxicol* 89, suppl I, 2001.
177. Larsen JT, Clemensen SV, Klitgaard NA, Nielsen B, **Brøsen K**. Clozapine-induced toxic hepatitis. *Ugeskr Laeger* 2001; 163(14): 2013-4.
- 178\* Kortunay S, Bozkurt A, Basci NE, **Brøsen K**, Kayaalp SO. Dose-dependent inhibition of the CYP2D6 catalyzed oxidation of sparteine by mepyramine in healthy volunteer. *Pharmacol Toxicol* 2001;89:331-4.
- 179\* Christensen PM, **Brøsen K**, Brixen KT, Beck-Nielsen H, Søgaard J, Kristiansen IS. Farmakoøkonomisk evalueringer af medicinsk behandling af osteoporose. *Ugeskr Laeger* 2002;164:1339-45.
- 180\* Jürgens G, Lange KH, Reuther L, Rasmussen BB, **Brøsen K**, Christensen HR. Effect of growth hormone on hepatic cytochrome P450 activities in healthy elderly men. *Clin Pharmacol Ther* 2002; 71:162-8.
- 181\* Jürgens G, Christensen HR, **Brøsen K**, Sonne J, Loft S, Olsen NV. Acute hypoxia and cytochrome P450-mediated hepatic drug metabolism in humans. *Clin Pharmacol Ther* 2002; 71:214-20
- 182' Rasmussen BB, Brix TH, Kyvik KO, **Brøsen K**. The interindividual differences in the 3-demethylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. *Pharmacogenetics* 2002; 12:473-8
- 183\* Breinholt VM, Offord EA, Brouwer C, Nielsen SE, **Brøsen K**, Friedberg T. In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids. *Food Chem Toxicol* 2002;40:609-16
- 184\* Christensen PM, **Brøsen K**, Brixen K, Kristiansen IS. Expressing effects of osteoporosis interventions in terms of postponing fractures. *Eur J Clin Pharmacol* 2002;58:629-33
- 185\* Justesen US, Klitgaard NA, **Brøsen K**, Pedersen C. Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers. *Br J Clin Pharmacol* 2003;55:100-6
- 186\* Pedersen RS, **Brøsen K**, Nielsen F. Enantioselective HPLC method for quantitative determination of tramadol and O-desmethyltramadol in plasma and urine: Application to clinical studies. *Chromatographia* 2003;57:279-85.

- 187\* Breinholt VM, Rasmussen SE, **Brøsen K**, Friedberg TH. In vitro metabolism of genistein and tangeretin by human and murine cytochrome P450s. *Pharmacol Toxicol.* 2003; 93:14-22.
- 188\* Christensen PM, **Brøsen K**, Brixen K, Andersen M, Kristiansen IS. A randomized trial of laypersons' perception of the benefit of osteoporosis therapy: number needed to treat versus postponement of hip fracture. *Clin Ther* 2003;25:2575-85.
189. **Brøsen K** *Pharmacol Toxicol.* Letter from the editor. 2004;94:1-2.
- 190\* Pedersen RS, Verstuyft C, Becquemont L, Jaillon P, **Brøsen K**. Cytochrome P4502C9 (CYP2C9) Genotypes in a Nordic Population in Denmark. *Bas Clin Pharmacol Toxicol.* 2004; 94:151-2.
- 191\* Bidstrup TB, Stilling N, Damkier P, Scharling B, Thomsen MS, **Brøsen K**. Rifampicin seems to act both an inducer and an inhibitor of the metabolism of repaglinide. *Eur J Clin Pharmacol* 2004;60:109-14
- 192\* Justesen US, Klitgaard NA, **Brøsen K**, Pedersen C. Dose-dependent pharmacokinetics of delavirdine in combination with amprenavir in healthy volunteers. *J Antimicrob Chemother* 2004;
- 193\* Justesen US, Andersen AB, Klitgaard NA, **Brøsen K**, Gerstoft J, Pedersen C. Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients. *Clin Infect Dis.* 2004;38:426-9.
194. **Brøsen K**. Some aspects of genetic polymorphism in the biotransformation of antidepressants. *Therapie* 2004; 59:5-12
195. **Brøsen K**. Letter from the editor. *Basic Clin Pharmacol Toxicol.* 2005; 96:1-2
- 196\* Laugesen S, Enggaard TP, Pedersen RS, Sindrup SH and **Brøsen K**. Paroxetine, a cytochrome P4502D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. *Clin Pharmacol Ther* 2005;77:312-23
197. **Brøsen K**. Klassisk farmakogenetik. *Ugeskr Læger* 2005;167:2143-6
198. Madsen H, **Brøsen K**, Frimodt-Møller N og Gahrn-hansen B. Antibiotika og overvægt. *Ugeskr Læger* 2005;167:2266-70
199. Pedersen RS, Damkier P, **Brøsen K**. Tramadol as a probe for cytochrome P4502D6 phenotyping: A population study. *Clin Pharmacol Ther* 2005;77:458-67
- 200\* Teilmann Larsen J, **Brøsen K**. Consumption of charcoal-broiled meat as an experimental tool for discerning CYP1A2-mediated drug metabolism *in vivo*. *Bas Clin Pharmacol Toxicol* 2005;97:141-8
- 201\* Pedersen RS, **Brøsen K**, Nielsen F. HPLC method for determination of rosiglitazone in plasma. *Chromatographia* 2005;62:197-201

- 202\* Halling J, Petersen MS, Damkier P, Nielsen F, Grandjean P, Weihe P, Lundgren S, Lundblad MS, **Brøsen K**. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. *Eur J Clin Pharmacol* 2005;61:491-7
203. **Brøsen K**. From the editor. *Basic Clin Pharmacol Toxicol*. 2005;97(4):201.
- 204\* Enggaard TP, Poulsen L, Arendt-Nielsen L, **Brøsen K**, Ossig J, Sindrup SH. The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. *Anesth Analg*. 2006;102(1):146-50.
- 205\* Bidstrup TB, Damkier P, Olsen AK, Ekblom M, Karlsson A, Brøsen K. The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide. *Br J Clin Pharmacol*. 2006;61:49-57.
- 206\* Skaalum Petersen M, Halling J, Damkier P, Nielsen F, Grandjean P, Weihe P and **Brøsen K**. Caffeine N3-demethylation (CYP1A2) in a population with increased exposure to polychlorinated biphenyls. *Eur J Clin Pharmacol* 2006;62:1041-8
- 207\* Pedersen RS, Damkier P, **Brøsen K**. The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects. *Br J Clin Pharmacol*. 2006 Dec;62(6):682-9. Epub 2006 Jul 12.
- 208\* Pedersen RS, Damkier P, **Brøsen K**. Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers. *Eur J Clin Pharmacol*. 2006 Jul;62(7):513-21. Epub 2006 Jun 9
- 209\* Noehr-Jensen L, Damkier P, Bidstrup TB, Pedersen RS, Nielsen F, **Brøsen K**. The relative bioavailability of loratadine administered as a chewing gum formulation in healthy volunteers. *Eur J Clin Pharmacol*. 2006 Jun; 62(6):437-45. Epub 2006 Apr 28.
- 210\* Andreasen AH, **Brøsen K**, Damkier P. A Comparative Pharmacokinetic Study in Healthy Volunteers of the Effect of Carbamazepine and Oxcarbazepine on CYP3A4. Published article online: 4-Jan-2007 doi: 10.1111/j.1528-1167.2007.00924.x
211. **Brøsen K**. Kønsforskelle i farmakologien. *Ugeskr Læger* 2007; 169(25): 2408-11
212. **Brøsen K**. Lægemedlers skæbne i organismen. Kap 3 i: Kampmann JP, Brøsen K, Simonsen U: *Basal og Klinisk Farmakologi* 2007, 3. udgave, FADLs Forlag, København, p. 67-92.
213. **Brøsen K**. Lægemedlers elimination. Kap 4 i: Kampmann JP, Brøsen K, Simonsen U: *Basal og Klinisk Farmakologi* 2007, 3. udgave, FADLs Forlag, København, p. 93-106.
214. **Brøsen K**. Farmakogenetik/-genomik. Kap 5 i: Kampmann JP, Brøsen K, Simonsen U: *Basal og Klinisk Farmakologi* 2007, 3. udgave, FADLs Forlag, København, p. 107-112.
215. **Brøsen K**, Christensen HR. Lægemedelinteraktioner. Kap 64 i: Kampmann JP, Brøsen K, Simonsen U: *Basal og Klinisk Farmakologi* 2007, 3. udgave, FADLs Forlag, København, p 717-22
216. **Brøsen K**. Styret terapi. Kap 73 i: Kampmann JP, Brøsen K, Simonsen U: *Basal og Klinisk Farmakologi* 2007, 3. udgave, FADLs Forlag, København, p. 805-7.

217. **Brøsen K**, Kampmann JP. Kap 74 i: Kampmann JP, Brøsen K, Simonsen U: Basal og Klinisk Farmakologi 2007, 3. udgave, FADLs Forlag, København, p. 809-18.
- 218\* Petersen MS, Halling J, Damkier P, Nielsen F, Grandjean P, Weihe P, **Brøsen K**. Polychlorinated biphenyl (PCB) induction of CYP3A4 enzyme activity in healthy Faroese adults. *Toxicol Appl Pharmacol.* 2007;224(2):202-6. Epub 2007 Jul 14
219. Tfelt-Hansen P, **Brøsen K**. Pharmacogenomics and migraine: possible implications. *J Headache Pain.* 2008 Jan 24, DOI 10.1007/s10194-008-0009-y [Epub ahead of print].
- 220\* Halling J, Weihe P, **Brøsen K**. The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population. *Br J Clin Pharmacol.* 2008;65(1):134-8. Epub 2007 Aug 31.
- 221\* Halling J, Petersen MS, Grandjean P, Weihe P, **Brøsen K**. Genetic predisposition to Parkinson's disease: CYP2D6 and HFE in the Faroe Islands. *Pharmacogenet Genomics.* 2008 Mar;18(3):209-212.
- 222\* Kragelund C, Hansen C, Torpet LA, Nauntofte B, **Brøsen K**, Pedersen AM, Buchwald C, Therkildsen MH, Reibel J. Expression of two drug-metabolizing cytochrome P450-enzymes in human salivary glands. *Oral Dis.* 2008 Feb 10
- 223\* Kragelund C, Hansen C, Torpet LA, Nauntofte B, **Brøsen K**, Pedersen AM, Buchwald C, Therkildsen MH, Reibel J. Expression of two drug-metabolizing cytochrome P450-enzymes in human salivary glands. *Oral Dis.* 2008 Feb 10; [Epub ahead of print]
- 224\* Otto M, Bach FW, Jensen TS, **Brøsen K**, Sindrup SH. Escitalopram in painful polyneuropathy: A randomized, placebo-controlled, cross-over trial. *Pain.* 2008 [Epub ahead of print].
- 225\* Halling J, Weihe P, **Brøsen K**. CYP2D6 polymorphism in relation to tramadol metabolism: a study of Faroese patients. *Ther Drug Monit.* 2008 30(3):271-5.
226. Vach W, Bergmann TK, **Brøsen K**. No evidence for taxane/platinum pharmacogen-etic markers: just lack of power? *J Clin Oncol.* 2008; 26(11):1903-4.
- 227\* Sorensen L, Nielsen B, Stage KB, **Brøsen K**, Damkier P. Implementation of a rational pharmacotherapy intervention for inpatients at a psychiatric department. *Nord J Psychiatry.* 2008;62(3):242-9.
- 228\* Kragelund C, Hansen C, Reibel J, Nauntofte B, **Brøsen K**, Pedersen AM, Smidt D, Eiberg H, Torpet LA. Polymorphic drug metabolizing CYP-enzymes--a pathogenic factor in oral lichen planus? *J Oral Pathol Med.* 2009 Jan;38(1):63-71.
- 229\* Zwisler ST, Enggaard TP, Noehr-Jensen L, Pedersen RS, Mikkelsen S, Nielsen F, **Brøsen K**, Sindrup SH. The Hypoalgesic Effect of Oxycodone in Human Experimental Pain Models in Relation to the CYP2D6 Oxidation Polymorphism. *Bas Clin Pharmacol Toxicol* 2009; 104(4): 335-344.
- 230\* Noehr-Jensen L, Zwisler ST, Larsen F, Sindrup SH, Damkier P, Nielsen F, **Brøsen K**. Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of

- pupillometry as a serotonergic biomarker. *Eur J Clin Pharmacol*. 2009 Sep;65(9):887-94. Epub 2009 Apr 29.
- 231\* Noehr-Jensen L, Zwisler ST, Damkier P, Larsen F, **Brøsen K**. Escitalopram is a weak inhibitor of the CYP2D6 catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain. *Clin Pharmacol Ther* 2009 Dec;86(6):626-33. Epub 2009 Aug 26
- 232\* Zwisler ST, Mikkelsen S, Enggaard TP, **Brøsen K**, Sindrup SH. Impact of CYP2D6 genotype on postoperative intravenous oxycodone analgesia. *Act Anaesth Scand* 2010 Feb;54(2):232-40. Epub 2009 Aug 31.
- 233\* Zwisler ST, Enggaard TP, Noehr-Jensen L, Mikkelsen S, Verstuyft C, Becquemont L, Sindrup SH, **Brøsen K**. The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes. *Fundam Clin Pharmacol* 2010;24(4):517-24
- 234\* Kragelund C, Hansen C, Reibel J, Nauntofte B, **Brøsen K**, Jensen SB, Torpet LA. Can the genotype or phenotype of two polymorphic drug metabolising cytochrome P450-enzymes identify oral lichenoid drug eruptions? *Journal of Oral Pathology* 2010: 39(6);497-505
- 235\* Nielsen A, Pedersen R, Noehr-Jensen L, Damkier P, **Brøsen K**. Two separate dose-dependent effects of paroxetine: mydriasis and inhibition of tramadol's O-demethylation via CYP2D6. *Eur J Clin Pharmacol* 2010: 66(7); 655-60.
- 236\* Pedersen RS, Brasch-Andersen C, Sim SC, Bergmann TK, Halling J, Petersen MS, Weihe P, Edvardsen H, Kristensen VN, **Brøsen K**, Ingelman-Sundberg M. Linkage disequilibrium between the CYP2C19 17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. *Eur J Clin Pharmacol* 2010. Dec;66(12):1199-1205. Jul 28. [Epub ahead of print].
- 237\* Birkett D, **Brøsen K**, Cascorbi I, Gustafsson LL, Maxwell S, Rago L, Sir Rawlins M, Reidenberg M, Sjöqvist F, Smith T, Thuerman P, Walubo A. Clinical pharmacology in research, teaching and health care: Considerations by IUPHAR, the International Union of Basic and Clinical Pharmacology. *Basic Clin Pharmacol Toxicol* 2010;107(1):531-59.
- 238\* Kjærstad MB, Nielsen F, Nøhr-Jensen L, Zwisler S, **Brøsen K**, Andersen HR. Systemic uptake of miconazole during vaginal suppository use and effect on CYP1A2 and CYP3A4 associated enzyme activities in women. *Eur J Clin Pharmacol*. 2010 Dec;66(12):1189-1197. Epub 2010 Oct 6
- 239.\* Bergmann TK, Brasch-Andersen C, Gréen H, Mirza M, Pedersen RS, Nielsen F, Skougaard K, Wihl J, Keldsen N, Damkier P, Friberg LE, Peterson C, Vach W, Karlsson MO, **Brøsen K**. Impact of CYP2C8\*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. *Pharmacogenomics J*. 2011 Apr;11(2):113-20. doi: 10.1038/tpj.2010.19
240. **Brøsen K**. Lægemidlers skæbne i organismen. I: *Basal og Klinisk Farmakologi* 4. udg. FADL's Forlag, 2010. Red. Kampmann JP, Brøsen K, Simonsen U. s. 61-86
241. **Brøsen K**. Lægemidlers elimination. I: *Basal og Klinisk Farmakologi* 4. udg. FADL's Forlag, 2010. Red. Kampmann JP, Brøsen K, Simonsen U. s. 87-99.

242. **Brøsen K.** Farmakogenetik. I: Basal og Klinisk Farmakologi 4. udg. FADL's Forlag, 2010. Red. Kampmann JP, Brøsen K, Simonsen U. s. 101-6.
243. **Brøsen K,** Christensen HR. Lægemiddelinteraktioner. I: Basal og Klinisk Farmakologi 4. udg. FADL's Forlag, 2010. Red. Kampmann JP, Brøsen K, Simonsen U. s.701-703.
244. **Brøsen K.** Styret terapi. I: Basal og Klinisk Farmakologi 4. udg. FADL's Forlag, 2010. Red. Kampmann JP, Brøsen K, Simonsen U. S. 801-3
245. **Brøsen K,** Christensen HR. Lægemiddelinteraktioner. I: Basal og Klinisk Farmakologi 4. udg. FADL's Forlag, 2010. Red. Kampmann JP, Brøsen K, Simonsen U. S. 807-14
- 246\* Bergmann TK, Gréen H, Brasch-Andersen C, Mirza MR, Herrstedt J, Hølund B, du Bois A, Damkier P, Vach W, **Brøsen K,** Peterson C. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. *Eur J Clin Pharmacol.* 2011;67(7):693-700 Feb 16.
- 247 **Brøsen K.** Lægemiddelinduceret hepatotoksicitet - glem ikke naturprodukter! *Ugeskr Læger* **2011**;173(34):2028
- 248\* Brasch-Andersen C, Møller MU, Christiansen L, Thinggaard M, Otto M, **Brøsen K,** Sindrup SH. A candidate gene study of serotonergic pathway genes and pain relief during treatment with escitalopram in patients with neuropathic pain shows significant association to serotonin receptor2C (HTR2C). *Eur J Clin Pharmacol.* **2011**;67:1131-7
- 249.\* Christensen MMH, Brasch-Andersen C, Green H, Nielsen F, Damkier P, Beck-Nielsen H, **Brøsen K.** Metformin Plasma Steady-State Levels and Glycosylated Hemoglobin, A1c (HbA1c) in patients with type 2 diabetes: Impact of gene variants in PMAT, OCT1, OCT2, MATE1 and MATE2. *Pharmacogenetics and Genomics* **2011**;21(12):837-850
- 250\* Zwisler ST, Enggaard TP, Mikkelsen S, Verstuyft C, Becquemont L, Sindrup SH, **Brøsen K.** Lack of Association of OPRM1 and ABCB1 Single-Nucleotide Polymorphisms to Oxycodone Response in Postoperative Pain. *J Clin Pharmacol.* **2012**; 52:234-242.
- 251\* Holmgaard R, Benfeldt E, Bangsgaard N, Sorensen JA, **Brøsen K,** Nielsen F, Nielsen JB. Probe Depth Matters in Dermal Microdialysis Sampling of Benzoic Acid after Topical Application: An ex vivo Study in Human Skin. *Skin Pharmacol Physiol* **2012**; 25:9-16 (DOI: 10.1159/000330491)
- 252\* Bergmann TK, Andersen CB, Gréen H, Mirza MR, Skougaard K, Wihl J, Keldsen N, Damkier P, Peterson C, Vach W, **Brøsen K.** Impact of ABCB1 Variants on Neutrophil Depression: A Pharmacogenomic Study of Paclitaxel in 92 Women with Ovarian Cancer. *Basic Clin Pharmacol Toxicol.* **2012**; 110: 199-204.
253. **Brøsen K.** BCPT Nordic Prize in Basic & Clinical Pharmacology & Toxicology for 2011 to Pertti J. Neuvonen. *Basic Clin Pharmacol Toxicol* 2012 Mar;110(3):205-6. Doi: 10.1111/j.1742-7843.2012.00859.x.
- 254\* Pedersen RS, Christensen MM, **Brøsen K.** Linkage disequilibrium between the CYP2C19 17 allele and other clinically important CYP2C allelic variants in a healthy Scandinavian population. *Eur J Clin Pharmacol* **2012**; 68(10):1463-4.

255. **Brøsen K.** Letter from the editor. *Basic Clin Pharmacol Toxicol* 2012 Dec;111(6):361. doi: 10.1111/bcpt.12030.
- 256\* Bergmann TK, Vach W, Feddersen S, Eckhoff L, Gréen H, Herrstedt J, **Brøsen K K.** GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients. *Acta Oncol.* 2013 52(4):871-4. doi: 10.3109/0284186X.2012.707787
- 257\* Stage TB, Christensen MM, Feddersen S, Beck-Nielsen H, **Brøsen K.** The role of genetic variants in CYP2C8, LPIN1, PPARGCA and PPARY on the trough steady-state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes. *Pharmacogenet Genomics* 2013; 23(4):219-27. doi: 10.1097/FPC.0b013e32835f91fc.
258. **Brøsen K.** Letter from the editor. *Basic Clin Pharmacol Toxicol* 2013 Jan;112(1):1. doi: 10.1111/bcpt.12040.
259. **Brøsen K.** BCPT Nordic Prize in Basic and Clinical Pharmacology and Toxicology for 2012 to Michael J. Mulvany. *Basic Clin Pharmacol Toxicol.* 2013 May;112(5):287-8. doi: 10.1111/bcpt.12053.
- 260\* Pedersen RS, Noehr-Jensen L, **Brøsen K.** The inhibitory effect of oral contraceptives on CYP2C19 activity is not significant in carriers of the CYP2C19 17 allele. *Clin Exp Pharmacol Physiol.* 2013;40(10):683-8. doi: 10.1111/1440-1681.12153.
- 261\* Christensen MM, Pedersen RS, Stage TB, Brasch-Andersen C, Nielsen F, Damkier P, Beck-Nielsen H, **Brøsen K.** A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. *Pharmacogenet Genomics.* 2013 Oct;23(10):526-34. doi: 10.1097/FPC.0b013e328364a57d
- 262\* Pedersen RS, Noehr-Jensen L, **Brøsen K.** The inhibitory effect of oral contraceptives on CYP2C19 activity is not significant in carriers of the CYP2C19 17 allele. *Clin Exp Pharmacol Physiol.* 2013;40(10):683-8. doi: 10.1111/1440-1681.12153.
- 263\* Pedersen RS, Damkier P, Christensen MM, **Brøsen K.** A cytochrome P450 phenotyping cocktail causing unexpected adverse reactions in female volunteers. *Eur J Clin Pharmacol.* 2013;69(12):1997-9
- 264\* Nielsen F, Christensen MMH, **Brøsen K.** Quantitation of Metformin in Human Plasma and Urine by Hydrophilic Interaction Liquid Chromatography and Application to a Pharmacokinetic Study. *Ther D Monit* 2014;36:211-7
- 265\* Pedersen RS, Nielsen F, Stage TB, Vinholt PJ, El-Achwah AB, Damkier P, **Brøsen K.** CYP2C19 17 increases the clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel. *Clin Exp Pharmacol Physiol.* 2014;441:870-8. doi: 10.1111/1440-1681.12297.
- 266\* Kragelund C, Jensen SB, Hansen C, **Brøsen K et. Al.** Subgrouping of patients with oral lichen planus according to cytochrome P450 enzyme phenotype and genotype. *Oral Surg Oral Med Oral Radiol* 2014;118: 469-74

267. **Brøsen K.** Lægemidlers skæbne I organismen. Kap 3, pp 55-84 i: "Basal og Klinisk Farmakologi", Brøsen K, Simonsen U, Kampmann JP and Thirstrup S (eds), 5. Edition FADL Publishing 2014.
268. **Brøsen K.** Lægemidlers elimination. Kap 4, pp 85-100 i: "Basal og Klinisk Farmakologi", Brøsen K, Simonsen U, Kampmann JP and Thirstrup S (eds), 5. Edition FADL Publishing 2014.
269. **Brøsen K.** Farmakogenetik/-genomik. Kap 5, pp101-8 i "Basal og Klinisk Farmakologi", Brøsen K, Simonsen U, Kampmann JP and Thirstrup S (eds), 5. Edition FADL Publishing 2014
270. **Brøsen K,** Christensen HR. Lægemiddelinteraktioner. Kap 5, pp 774-9 i: "Basal og Klinisk Farmakologi", Brøsen K, Simonsen U, Kampmann JP and Thirstrup S (eds), 5. Edition FADL Publishing 2014.
271. Damkier P, **Brøsen K.** Styret terapi og biomarkører. Kap 74, pp 873-7 i: "Basal og Klinisk Farmakologi", Brøsen K, Simonsen U, Kampmann JP and Thirstrup S (eds), 5. Edition FADL Publishing 2014.
272. Hallas J, Andersen M, **Brøsen K.** Lægemiddelforbrug. Kap 76, pp 888-91 i: "Basal og Klinisk Farmakologi", Brøsen K, Simonsen U, Kampmann JP and Thirstrup S (eds), 5. Edition FADL Publishing 2014.
273. **Brøsen K,** Damkier P. Genomet og farmakologien [The genome and Pharmacology. Ugeskr Læge 2014;176:2183-6
- 274\* Stage TB, Pedersen RS, Damkier P, Christensen MM, Feddersen S, Larsen JT, Højlund K, **Brøsen K.** Intake of St. John's wort improves the glucose tolerance in healthy subjects that ingest metformin compared to metformin alone. Br J Clin Pharmacol 2015;79:298-306 doi: 10.1111/bcp.12510.
- 275\* Stage TB, Damkier P, Pedersen RS, Christensen MM, Christiansen L, Christensen K, **Brøsen K.** A twin study of the trough plasma steady-state concentration of metformin. Pharmacogenet Genomics. 2015;25:259-62
- 276\* Holbech JV, Bach FW, Finnerup NB, **Brøsen K,** Jensen TS, Sindrup SH. Pain. 2015 Feb 19. Imipramine and Pregabalin Combination for Painful Polyneuropathy. A Randomized Controlled Trial. Pain. 2015 May;156(5):958-66. doi: 10.1097.
- 277\* Christoffersen DJ, Brasch-Andersen C, Thomsen JL, Worm-Leonhard M, Damkier P, **Brøsen K.** Quantification of morphine, morphine 6-glucuronide, buprenorphine, and the enantiomers of methadone by enantioselective mass spectrometric chromatography in whole blood. Forensic Sci Med Pathol. 2015 Jun;11(2):193-201. doi: 10.1007/s12024-015-9673-9. Epub 2015 Mar 24.
- 278\* Christensen MM, Højlund K, Hother-Nielsen O, Stage TB, Damkier P, Beck-Nielsen H, **Brøsen K.** Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers. Eur J Clin Pharmacol. 2015 Jun;71(6):691-7. doi: 10.1007/s00228-015-1853-8. Epub 2015 May 5.

- 279\* **Brøsen K.** Pharmacogenetics of drug oxidation via cytochrome P450 (CYP) in the populations of Denmark, Faroe Islands and Greenland. *Drug Metabol Personal Ther.* 2015;30(3)\_147-63. Jan 23. pii: /j/dmdi.ahead-of-print/dmdi-2014-0029/dmdi-2014-0029.xml. doi: 10.1515/dmdi-2014-0029.
- 280\* Stage TB, **Brøsen K**, Christensen MM. A Comprehensive Review of Drug-Drug Interactions with Metformin. *Clin Pharmacokinet.* 2015 54(8):811-24. doi: 10.1007/s40262-015-0270-6
- 281\* Lassen D, Damkier P, **Brøsen K.** The Pharmacogenetics of Tramadol. *Clin Pharmacokinet.* 2015 54(8):825-36. doi: 10.1007/s40262-015-0268-0.
- 282\* Lee MY, Apellániz-Ruiz M, Johansson I, Vikingsson S, Bergmann TK, **Brøsen K**, Green H, Rodríguez-Antona C, Ingelman-Sundberg M. Role of cytochrome P450 2C8 3 (CYP2C8 3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity. *Pharmacogenomics* 2015 6(9):929-37. doi: 10.2217/pgs.15.46. Epub 2015 Jun 26.
- 283\* Apellaniz-Ruiz M, Sanchez-Barroso L, Gutierrez-Gutierrez G, Sereno M, García-Donas J, Åvall-Lundqvist E, Green H, **Brøsen K**, Bergmann TK, and Rodríguez-Antona C. Replication of genetic polymorphisms reported to be associated with taxane related sensory neuropathy in patients with early breast cancer treated with paclitaxel. *Clin Cancer Research* 2015 21(13):3092-3. doi: 10.1158/1078-0432.CCR-14-1885.
- 284 **Brøsen K.** Professor Olavi Pelkonen is the 2014 BCPT Nordic Prize Winner in Basic and Clinical Pharmacology and Toxicology. *Basic Clin Pharmacol Toxicol.* 2015 Sep;117(3):145-6
- 285\* Christensen MM, Højlund K, Hother-Nielsen O, Stage TB, Damkier P, Beck-Nielsen H, **Brøsen K.** Endogenous glucose production increases in response to metformin treatment in the glycogen-depleted state in humans: a randomised trial. *Diabetologia.* 2015 Nov;58(11):2494-502.
- 286 Larsen JK, Krogh-Nielsen L, **Brøsen K.** The use of the monoamine oxidase inhibitor isocarboxazide in treatment-resistant depression]. *Ugeskr Laeger.* 2015 Dec 21;177(52).
- 287\* Stage TB, Pottegård A, Henriksen DP, Christensen MM, Højlund K, **Brøsen K**, Damkier P. Initiation of glucose-lowering treatment decreases international normalized ratio levels among users of vitamin K antagonists: a self-controlled register study. *J Thromb Haemost.* 2016 Jan;14(1):129-33. doi:
- 288\* Stage TB, Damkier P, Christensen MM, Nielsen LB, Højlund K, **Brøsen K.** Impaired Glucose Tolerance in Healthy Men Treated with St. John's Wort. *Basic Clin Pharmacol Toxicol.* 2015 2016 Mar;118(3):219-24. doi: 10.1111/bcpt.12486.
- 289\* Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, **Brøsen K.** Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60-year-old Caucasian woman with ovarian carcinoma. *Br J Clin Pharmacol.* 2016;81:313-5.
- 290\* Stage TB, Lee MP, Hallas J, Christensen MM, **Brøsen K**, Christensen K, Gagne JJ, Pottegård A. Early Discontinuation of Metformin in Individuals Treated with Inhibitors of

Transporters of Metformin. *Basic Clin Pharmacol Toxicol*. 2016 Jun;118(6):487-95. doi: 10.1111/bcpt.12579. Epub 2016 Apr 25. PMID: 27128732

- 291\* Christoffersen DJ, Damkier P, Feddersen S, Möller S, Thomsen JL, Brasch-Andersen C, **Brøsen K**. The ABCB1, rs9282564, AG and TT Genotypes and the COMT, rs4680, AA Genotype are less frequent in Deceased Patients with Opioid Addiction (DOA) than in Living Patients with Opioid Addiction (LOA). *Basic Clin Pharmacol Toxicol*. 2016 Apr 9. doi: 10.1111/bcpt.12602.
- 292\* Nguyen A, Stage TB, Feddersen S, Christoffersen DJ; Christensen MM, Damkier P; Thomsen JL, **Brøsen K**. Carriers of genetic variants in the HNF1A gene are more common among dead opioid addicts than among living addicts. *Eur J Clin Pharmacol* 2016;72(9):1159-60
- 293\* Santoro AB, Stage TB, Struchiner CJ, Christensen MM, **Brøsen K**, Suarez-Kurtz G. Limited sampling strategy for determining metformin area under the plasma concentration-time curve. *Br J Clin Pharmacol*. 2016 Oct;82(4):1002-10. doi: 10.1111/bcp.13049. Epub 2016 Jul 24
- 294\* Gormsen LC, Sundelin EI, Jensen JB, Vendelbo MH, Jakobsen S, Munk OL, Christensen MM, **Brøsen K**, Frøkiær J, Jessen N. In Vivo Imaging of Human 11C-Metformin in Peripheral Organs: Dosimetry, Biodistribution and Kinetic Analyses. *J Nucl Med*. 2016;57(12):1920-6
- 295\* **Brøsen K**, Andersen SE, Borregaard J, Christensen HR, Christensen PM, Dalhoff KP, Damkier P, Hallas J, Heisterberg J, Jessen N, Jürgens G, Kampmann JP, Laursen BE, Laursen T, Nielsen LP, Poulsen BK, Poulsen HE, Andersen LV, Senderovitz T, Sonne J. Clinical Pharmacology in Denmark in 2016 - 40 Years with the Danish Society of Clinical Pharmacology and 20 Years as a Medical Speciality. *Basic Clin Pharmacol Toxicol*. 2016 Dec;119(6):523-532. doi: 10.1111/bcpt.12681
- 296\* Dujic T, Zhou K, Yee SW, van Leeuwen N, de Keyser CE, Javorský M, Goswami S, Zaharenko L, Christensen MM, Out M, Tavendale R, Kubo M, Hedderson MM, van der Heijden AA, Klimčáková L, Pirags V, Kooy A, **Brøsen K**, Klovins J, Semiz S, Tkáč I, Stricker BH, Palmer CN, 't Hart LM, Giacomini KM, Pearson ER. Variants in Pharmacokinetic Transporters and Glycaemic Response to Metformin: A MetGen Meta-Analysis. *Clin Pharmacol Ther*. 2017 Jun;101(6):763-772. doi: 10.1002/cpt.567
- 297\* Nguyen A, Stage TB, Feddersen S, Christoffersen DJ, Christensen MM, Damkier P, Thomsen JL, **Brøsen K**. Erratum to: Carriers of genetic variants in the HNF1A gene are more common among dead opioid addicts than among living addicts. *Eur J Clin Pharmacol*. 2017 Feb;73(2):255.
- 298 **Brøsen K**, Funck-Brentano C, Kroemer HK, Pirmohamed M, Schwab M. Open letter on access to the BIA 10-2474 clinical trial data. *Lancet*. 2017 Jan 14;389(10065):156. doi: 10.1016/S0140-6736(16)32515-6.
- 299\* Nielsen LM, Sverrisdóttir E, Stage TB, Feddersen S, **Brøsen K**, Christrup LL, Drewes AM, Olesen AE. Lack of genetic association between OCT1, ABCB1, and UGT2B7 variants and morphine pharmacokinetics. *Eur J Pharm Sci*. 2017 Mar 1;99:337-342. doi: 10.1016/j.ejps.2016.12.039.

- 300\* Agergaard K, Mau-Sørensen M, Stage TB, Jørgensen TL, Hassel RE, Steffensen KD, Pedersen JW, Milo ML, Poulsen SH, Pottegård A, Hallas J, **Brøsen K**, Bergmann TK. Clopidogrel paclitaxel drug-drug interaction: A pharmacoepidemiologic study. *Clin Pharmacol Ther.* 2017 Sep;102(3):547-553. doi: 10.1002/cpt.674
- 301\* Madsen MJ, Bergmann TK, **Brøsen K**, Thiesson HC. The Pharmacogenetics of Tacrolimus in Corticosteroid-Sparse Pediatric and Adult Kidney Transplant Recipients. *Drugs R D.* 2017;2:279-286 doi: 10.1007/s40268-017-0177-9.
- 302\* Sindrup SH, Holbech JV, Bach FW, Finnerup NB, **Brøsen K**, Jensen TS. The Impact of Serum Drug Concentration on the Efficacy of Imipramine, Pregabalin and their Combination in Painful Polyneuropathy. *Clin J Pain.* 2017 2017 Dec;33(12):1047-1052. doi: 10.1097/doi:
- 303\* Sundelin E; Gormsen L C, Jensen JB, Vendelbo MH, Jakobsen S, Munk OL, Christensen M; **Brøsen K**, Frokiaer J, Jessen, N. Genetic Polymorphisms in Organic Cation Transporter 1 Attenuates Hepatic Metformin Exposure in Humans. *Clinical Pharmacology and Therapeutics* 2017 Nov;102(5):841-848. doi: 10.1002
- 304\* Stage TB, Graff M, Wong S, Rasmussen LL, Nielsen F, Pottegård A, **Brøsen K**, Kroetz DL, Khojasteh SC, Damkier P. Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro. *Br J Clin Pharmacol.* 2018 Mar;84(3):510-519. doi: 10.1111/bcp.13467
- 305\* McCreight LJ, Stage TB, Connelly P, Lonergan M, Nielsen F, Prehn C, Adamski J, **Brøsen K**, Pearson ER. Pharmacokinetics of metformin in patients with gastrointestinal intolerance. *Diabetes Obes Metab.* 2018 Jul;20(7):1593-1601. doi: 10.1111/dom.13264
- 306\* Stage TB, Christensen MH, Jørgensen NR, Beck-Nielsen H, **Brøsen K**, Gram J, Frost M. Effects of metformin, rosiglitazone and insulin on bone metabolism in patients with type 2 diabetes. *Bone.* 2018 Jul; 112:35-41. doi: 10.1016/j.bone.2018.04.004.
- 307\* Pottegård A, Broe A, Stage TB, **Brøsen K**, Hallas J, Damkier P. Use of Dicloxacillin and Risk of Pregnancy among Users of Oral Contraceptives. *Basic Clin Pharmacol Toxicol* 2018 Sep;123(3):288-293. doi: 10.1111/bcpt.13000.
- 308\* **Brøsen K** and Damkier P (eds.). *Pharmacogenetics*. In: *Advances in Pharmacology* (Enna S (serial editor), Academic Press – An imprint of Elsevier
- 309\* Stage TB, Wellhagen G, Christensen MM, Guiastrenec B, **Brøsen K**, Kjellson M. Using a semi-mechanistic model to identify the main sources of variability of metformin pharmacokinetics. *Basic Clin Pharmacol Toxicol* 2019 Jan;124(1):105-114. doi: 10.1111/bcpt.13139
- 310\* Gormsen LC, Søndergaard E, Christensen NL, **Brøsen K**, Jessen N, Nielsen S Metformin increases endogenous glucose production in non-diabetic individuals and individuals with recent-onset type 2 diabetes. *Diabetologia.* 2019 Jul;62(7):1251-1256. doi: 10.1007/s00125-019-4872-7. PMID: 30976851
- 311\* Sundelin EIO, Gormsen LC, Heebøll S, Vendelbo MH, Jakobsen S, Munk OL, Feddersen S, **Brøsen K**, Hamilton-Dutoit SJ, Pedersen SB, Grønbaek H, Jessen N. Hepatic exposure of metformin in patients with non-alcoholic fatty liver disease. *Br J Clin Pharmacol.* 2019 Aug;85(8):1761-1770. doi: 10.1111/bcp.13962

- 312\* Mirza MR, Bergmann TK, Mau-Sørensen M, Christensen RD, Åvall-Lundqvist E, Birrer MJ, Jørgensen M, Roed H, Malander S, Nielsen F, Lassen U, **Brøsen K**, Bjørge L, Mäenpää J. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24. *Cancer Chemother Pharmacol*. 2019 Oct;84(4):791-798. doi: 10.1007/s00280-019-03917-z. Epub 2019 Aug 2.
- 313 **Brøsen K**. Lægemedlers skæbne i organismen. Kap 3 (side 68-p99) i: Basal og klinisk farmakologi, 6. udgave 2019. Brøsen K, Simonsen U, Dalhoff K. FADL's Forlag, København
- 314 **Brøsen K**. Lægemedlers elimination. Kap 4 (side 100-118) i Basal og klinisk farmakologi, 6. udgave 2019. Brøsen K, Simonsen U, Dalhoff K. FADL's Forlag, København.
- 315 **Brøsen K**. Farmakogenetik/farmakogenomik. Kap 5 (119-27) i Basal og klinisk farmakologi, 6. udgave 2019. Brøsen K, Simonsen U, Dalhoff K. FADL's Forlag, København.
- 316 Bergmann TK, **Brøsen K** Christensen HR. Lægemeddelinteraktioner. Kap 66 (992-1000) i Basal og klinisk farmakologi, 6. udgave 2019. Brøsen K, Simonsen U, Dalhoff K. FADL's Forlag, København.
- 317 Damkier P, **Brøsen K**. Styret terapi og biomarkører. Kap 75 (1119-1125) i Basal og klinisk farmakologi, 6. udgave 2019. Brøsen K, Simonsen U, Dalhoff K. FADL's Forlag, København
- 318 Hallas J, Andersen M, **Brøsen K**. Lægemedelforbrug. Kap 77 (1138-1142) i Basal og klinisk farmakologi, 6. udgave 2019. Brøsen K, Simonsen U, Dalhoff K. FADL's Forlag, København.
- 319\* Frederiksen T, Areberg J, Schmidt E, Stage TB, **Brøsen K**. Quantification of In Vivo Metabolic Activity of CYP2D6 Genotypes and Alleles through Population Pharmacokinetic Analysis of Vortioxetine. *Clin Pharmacol Ther*. 2020 Jun 29. doi: 10.1002/cpt.1972. Online ahead of print.
- 320\* Kuhlmann I, Arnspang Pedersen S, Skov Esbech P, Bjerregaard Stage T, Hougaard Christensen MM, **Brøsen K**. Using a limited sampling strategy to investigate the interindividual pharmacokinetic variability in metformin: A large prospective trial. *Br J Clin Pharmacol*. 2020 Oct 28. doi: 10.1111/bcp.14591. Online ahead of print. PMID: 33118168
- 321\* Larsen AH, Jessen N, Nørrelund H, Tolbod LP, Harms HJ, Feddersen S, Nielsen F, **Brøsen K**, Hansson NH, Frøkiaer J, Poulsen SH, Sørensen J, Wiggers H. A randomised, double-blind, placebo-controlled trial of metformin on myocardial efficiency in insulin-resistant chronic heart failure patients without diabetes. *Eur J Heart Fail*. 2019 Dec 21. doi: 10.1002/ejhf.1656. [Epub ahead of print]. PMID: 31863557

Number of citations (2 February 2021) and H-index according to Scopus: 13781, H-index: 66 and according to Web of Science: 12989 and H-index: 65. Highly cited researcher in pharmacology from 2001 to 15

\* Original scientific papers or review papers in international scientific journals with peer review. Updated 2 February 2021